对少数族裔人群前列腺癌筛查指南的担忧
本文关注前列腺特异性抗原(PSA)在前列腺癌筛查中灰区4–10 ng/ml特异性不足的问题,指出二次筛查工具(如多参数磁共振成像及生物标志物)在黑人等高危人群中的特异性与阴性预测值尚缺乏评估。作者建议对NCCN指南支持的PSA≥3.0 ng/ml阈值及二次筛查工具阈值进行建模或前瞻性评估,并在指南制定中纳入社区医疗服务提供者。
要点
- PSA在4–10 ng/ml灰区对临床显著的前列腺癌(Gleason分级组2–5)特异性低,导致不必要的阴性活检和过度检出。
- NCCN早期检测指南明确要求用生物标志物和MRI提高PSA特异性。
- 多数二次筛查生物标志物在黑人男性中未评估特异性和阴性预测值,而高危人群阴性预测值会下降。
核心结论
- 作者认为,在告知男性放弃前列腺活检前,应评估生物标志物在高灵敏度的特异性、校准度及在不同Gleason分级组2–5患病率人群中的阴性预测值。
- 作者建议对NCCN指南支持的PSA≥3.0 ng/ml阈值及当前推荐的二次筛查工具阈值进行建模或前瞻性评估,以判断其风险效益比是否可接受。
研究设计与样本
- 本文为针对前列腺癌筛查指南的评论文章,未报告系统检索范围或样本量。
主要发现
- PSA是前列腺癌筛查推荐的一线血清生物标志物,但在4–10 ng/ml灰区特异性存在关键局限。
- 对临床显著的Gleason分级组2–5前列腺癌特异性低,导致不必要的阴性活检、惰性癌过度检出和过度治疗,尤其在预后良好的黑人男性中。
- 泌尿外科界依赖二次筛查工具(如多参数磁共振成像)提高对Gleason分级组2–5前列腺癌的特异性与灵敏度。
- 当前NCCN早期检测指南明确要求用生物标志物和MRI提高PSA特异性。
- 泌尿外科医生依赖二次筛查工具对Gleason分级组2–5前列腺癌的阴性预测值,为PSA升高的男性推迟活检;但任何所选阈值的阴性预测值在高Gleason分级组2–5患病率人群中会下降。
关键数值与推荐
- NCCN早期检测指南明确要求用生物标志物和MRI提高PSA特异性。
- NCCN指南支持PSA≥3.0 ng/ml阈值。
- 多数常用二次生物标志物的特异性和阴性预测值尚未在黑人男性中评估。
- 应评估预测风险与观察风险的相关性(即校准度)在高和低前列腺癌风险人群(如黑人和亚洲男性)中的表现。
临床怎么用
- 作者认为,在告知男性放弃前列腺活检前,应评估生物标志物在高灵敏度的特异性、校准度及在不同Gleason分级组2–5患病率人群中的阴性预测值。
- 作者建议对NCCN指南支持的PSA≥3.0 ng/ml阈值及当前推荐的二次筛查工具阈值进行建模或前瞻性评估,以判断其风险效益比是否可接受。
- 作者提出,临床、生物标志物和影像整合的按种族分层风险计算器及统计建模可用于改善少数族裔筛查结局。
- 作者建议指南应纳入社区医疗服务提供者,以更好反映美国资源有限的环境。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-Specific Antigen (PSA) is a first-line recommended serum biomarker used for prostate cancer (PCa) screening. However, this test has critical limitations in specificity within the gray zone of PSA from 4–10 ng/ml. The low specificity for clinically significant Gleason grade group 2–5 (GG2–5) PCa leads to unnecessary negative biopsies, over-detection of indolent cancers, and over-treatment, especially in Black men with favorable risk PCa. The urological community relies on secondary screening tools to augment specificity and increase sensitivity for GG2–5 PCa such as multiparametric magnetic resonance imaging of the prostate (MRI). Current National Comprehensive Cancer Network (NCCN) Early Detection guidelines specifically call for biomarkers and MRI tests to improve the specificity of PSA. Urologists rely on the negative predictive value (NPV) of the secondary screening tools for GG2–5 PCa to defer biopsies for men with elevated PSA. However, the NPV of any threshold chosen decreases in populations with a high prevalence of GG2–5 PCa. For most of these popular secondary biomarkers, specificity and NPV have not been assessed in Black men despite their known high risk. It is necessary to focus on other aspects of accuracy like specificity, NPV and the correlation of predicted risk versus observed risk (i.e., calibration) in populations with both high and low PCa risk (e.g., Black and Asian men). The impact of the new NCCN guideline-supported PSA ≥ 3.0 ng/ml threshold and the currently recommended thresholds of the secondary screening tools should be modeled or prospectively evaluated to see if they provide an acceptable risk-benefit ratio. Beyond discrimination/area under the curve, biomarkers should be evaluated for their calibration, specificity at high sensitivity, and their NPV for men with varied prevalence of GG2–5 PCa before being told to forego prostate biopsy. Clinical, biomarker, and imaging-integrated race stratified risk calculators and statistical modeling can be used to improve screening outcomes in minorities. Guidelines should also involve community providers to better reflect the resource limited settings within the US.
引用
- Sweis J, Ofori B, Murphy AB, et al. Concerns regarding prostate cancer screening guidelines in minority populations. Prostate Cancer Prostatic Dis. 2023. PMID: 38114597. doi:10.1038/s41391-023-00765-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。